Old name, new purpose: why we’ve gone back to RNID

  1. Home
  2. Our research into hearing loss and tinnitus
  3. Developing new treatments: the Hearing Therapeutics Initiative

Developing new treatments: the Hearing Therapeutics Initiative

Across the UK, 12 million people have hearing loss and 1 in 7 adults live with tinnitus. Despite this, there are not yet any clinically approved treatments for those who need and want them.

The RNID Hearing Therapeutics Initiative accelerates the global development of new treatments and therapeutics to prevent and treat hearing loss and tinnitus.

We do this by creating partnerships across the global hearing research ecosystem – from hearing researchers and clinicians, and funders and investors, to those working in biotech, pharma and hearing device companies. If that sounds like you, sign up to join the network below.

How the HTI works

The Hearing Therapeutics Initiative brings together:

  • a consortium of partner organisations with unique knowledge, expertise and infrastructure in hearing research, drug discovery and development.
  • a global Network of innovators from academia and industry looking for tailored support to help them develop new hearing therapeutics.

The Hearing Therapeutics Initiative connects innovators with the infrastructure and expertise they need, at every step of the translational pathway.

By joining the Network you’ll receive tailored support for your translational research, bi-monthly newsletters with updates on the hearing therapeutics sector, consulting and collaboration opportunities, and invitations to HTI activities and events.

Join the HTI Network

Explore more

Page last updated: 5 September 2023

Back to top